Spheroid breast cancer model to select individual treatments
Company 2016
SpheroTec GmbH, Martinsried, Germany
Treatment for HER2+ breast cancer patients has greatly improved prognosis in recent years. However, there is a lack of specific treatment for HER2- breast tumors. Thus, there is a need to develop tools that allow for a better patient-specific drug screening that can increase treatment efficacy. Here, an in vitro tissue human breast tumor spheroid model was used to test different compounds and compared to homogenous cell tumors generated with HER2- human breast cancer lines. The results showed cell line-based spheroids had higher metabolic activity and cell viability and this was correlated to a lower number of cells in the tumor model, contrary to heterogeneous spheroids. Moreover, except for taxanes, most of the compounds had differential responses between tissue models and breast cancer cell lines spheroids. Finally, tissue-based spheroids presented high variability in drug responses and corresponded to current guidelines recommendations. Overall, the researchers present a model that can potentially be used as a diagnostic tool to select efficient treatment strategies in individual patients.
Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids
Barbara Mayer
Added on: 10-05-2021
[1] https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0855-3[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38[3] https://www.spherotec.com/
